A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 06 Jul 2019 This trial has been discontinued in Austria, according to European Clinical Trials Database.
- 27 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 02 May 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.